Definium Therapeutics

The phase‑3 Panorama trial of DT120 in generalized anxiety disorder met its primary endpoints, strengthening Definium Therapeutics' approval prospects. The company focuses on psychedelic‑based therapies for neurological disorders, targeting large and growing treatment markets. Bank of America raised its price target to $91 and expects peak sales of up to $13.2 billion and roughly 130% upside. » Más en finanzen.net

Definium Therapeutics shares climbed 20.7% in premarket trading after the phase‑3 study “Panorama” for DT120 ODT (Lysergid/LSD) in adults with generalized anxiety disorder met its primary endpoint. At week 12 the placebo‑corrected reduction on the HAM‑A scale was 5.1 points, with a highly significant p‑value and an effect size of 0.64. The results follow an earlier positive phase‑3 outcome (Voyage) and the recently granted FDA breakthrough therapy designation for DT120 in MDD, prompting numerous analysts to issue buy ratings. Investors are now focused on approval timelines and DT120’s potential as a first‑in‑class therapy for GAS and MDD. » Más en de.investing.com

The Phase‑3 Voyage study showed that DT120 ODT (pharmaceutically optimized LSD formulation) met the primary endpoint and all key secondary endpoints in generalized anxiety disorder, with a statistically significant reduction in HAM‑A score and a higher response rate versus placebo. Treatment was generally well tolerated; adverse events were mild to moderate and mostly occurred on the day of dosing. This is the second positive Phase‑3 readout following the Emerge depression results; further Panorama data are expected in September 2026. According to the company, Definium holds roughly $1.1 billion in cash and views its financing as secured through 2030. » Más en finanzen.net